1. ProteoNova™ Inc. Overview © 2008 ProteoNova™, Inc.

2. The Company ProteoNova is a biotechnology company located in Pasadena, California. The Company has developed a platform technology that …..… accelerates the development of novel proteins for therapeutic and diagnostic uses, and …. …. has broad applications – including for humans, livestock, and crop plants. Next

3. The Company has patented novel methods that…. …. use a proprietary DNA library…. …. link proteins with their coding messages…. …. use accelerated protein evolution and specialized selection techniques…. …. to rapidly and inexpensively make novel protein products. The Technology Next

4. Potential Markets Human Pharmaceuticals Vaccines Diagnostics Veterinary Drugs Biowarfare Agriculture Enzymes Industrial Chemicals Next The technology can be used to develop products in the following categories:

5. How the Technology Works An illustration of the Company’s overall approach for generating novel proteins…. Next

6. Protein Evolution in Practice DNA Library ProteoNova Selection Technologies Translated mRNA pool Enriched and selected cDNAs Translated Protein Optimize Selected cDNAs by error prone PCR Test for functional activity Next

7. 5’ ProteoNova’s Proprietary DNA Library 3’ Linker The reading frame of the oligos in the library is random. The library is extremely large, > 1x10 14 different sequences. It is biased to produce hydrophilic proteins. The library produces proteins ~100 amino acids long. The sequences in the library are labeled with a light activatable linker. Next

8. 360nm Light activates the linker, and thereby, crosslinks the mRNA with the ultimate tRNA The modified mRNA occupies the last codon and accepts the protein thus forming an mRNA-tRNA-Protein complex Light activatable cross linker on last codon of the mRNAs from proprietary DNA library The Linker Technology Next 5’3’ 5’ Protein tRNA mRNA Complex 5’ Puromycin Ribosome In Vitro transcription/ translation

9. ProteoNova’s Various Linker Methods Puromycin on 3’ Linker on anticodon Linker on mRNA Puromycin on 3’ Linker on mRNA Complex 360 nm irradiation In vitro translationMethods Next

10. Real time PCR of cDNA Taq DNA Polymerase Taq DNA Polymerase Reverse transcribe mRNA to cDNA using reverse transcriptase, nucleotides and primers c-DNA NS Protein-tRNA-mRNA complexes reacted with Target molecule affixed to solid substrate, i.e.. magnetic beads Transcribe/translate the library using ProteoNova’s linker technology Protein-tRNA-mRNA complex Selection Process 5’3’ linker DNA Library Next Purify the protein and configure for preclinical testing Introduce the DNA into host cells or organism Target molecule Bioreactor culture

11. Rnd 1Rnd 3Rnd 2Rnd 1Rnd 2 0 1 2 3 4 5 6 7 8 9 Months Transcribe/translate library select for product make enough for testing test in vitro a viable product expected within three rounds of selection Product that tests efficacious in vitro is then tested in vivo in animal model(s) a viable product expected within two rounds of selection In vitro testing Phase I In vivo testing in animals Phase II Pre-clinical testing Pre-Clinical Testing Next

12. Intellectual Property  Three U.S. patents have been issued  Six patent applications are pending in the U.S.  The Company has a patent issued in Australia, and patents pending in the EU, Japan, Hong Kong and Canada  The ProteoNova, Inc. name is trademarked in the U.S. and is a registered trademark in the EU Next

13. Summary  It dramatically reduces the time, labor and cost for producing proteins with specific properties.  The system can be used to create effective vaccines, more sensitive and specific diagnostics, and virtually any therapeutic where antibodies are currently used.  The technology is protected with a broad patent portfolio. ProteoNova’s technology is a powerful platform technology that harnesses the power of accelerated protein evolution and in vitro mRNA and tRNA display to greatly simplify production of novel proteins. Next

14. Contact Information For further information, please direct queries to: Robert Guerrero, Ph.D. CEO ProteoNova, Inc. 814 South Euclid Avenue Pasadena, California 91106 Telephone:626-793-9970 Facsimile:626-795-2599 E-mail:robertrguerrero@cs.com ProteoNova™ Inc.